Council for the Central Laboratory of the Research Councils

Maple Leaf Foods presents 13th annual Food Safety Symposium to bridge the gap on food safety and sustainability

Retrieved on: 
Wednesday, October 25, 2023
Maple Leaf Foods, Wood, Food safety, Sanitation, Loblaw Companies, Food industry, Sustainability, Technical Service Bulletin, Associate, Health, Food, MFI, Industrial engineering, Corporation, MGL, Learning, Environment, Golden, Council for the Central Laboratory of the Research Councils, Partnership, Farmer, Food packaging, University, University of Guelph, Chief sustainability officer, TSX, Management, Agriculture, Quality

(TSX: MFI), yesterday held its 13th annual Food Safety Symposium as part of the company's commitment to providing safe food for all Canadians and foster knowledge sharing among experts within the food industry.

Key Points: 
  • (TSX: MFI), yesterday held its 13th annual Food Safety Symposium as part of the company's commitment to providing safe food for all Canadians and foster knowledge sharing among experts within the food industry.
  • With the theme Bridging the Gap: A Symposium on Food Safety and Sustainability, the symposium began with an introduction from Maple Leaf Foods' President and CEO, Curtis Frank, and Chief Food Safety and Sustainability Officer, Randy Huffman.
  • Keynote speaker, Evan Fraser, Director, Arrell Food Institute, University of Guelph, spoke on the topic of the future of food.
  • Next year's Maple Leaf Foods' Food Safety Symposium date will be announced soon.

Labcorp Announces 2023 First Quarter Results

Retrieved on: 
Tuesday, April 25, 2023
Capital expenditure, COVID-19 testing, Corporate social responsibility, Launch pad, COVID-19, Drug, LH, COVID, FSP, Public expenditure, Acquisition, Laboratory, Corporation, Capital, Council for the Central Laboratory of the Research Councils, Growth, Weather, EPS, NHP, Health, NYSE, PCR, Ascension, Management, Pharmaceutical industry, Video game, Public utility, Labcorp

BURLINGTON, N.C., April 25, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

Key Points: 
  • BURLINGTON, N.C., April 25, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.
  • In the first quarter, Labcorp executed against its strategic plan to position the business for both short- and long-term growth.
  • Revenue for the quarter was $3.78 billion, a decrease of (3.1%) from $3.90 billion in the first quarter of 2022.
  • Labcorp is updating 2023 full year guidance to reflect its first quarter performance and full year outlook.

ACRO Announces 2023 Officers and New Member

Retrieved on: 
Monday, March 6, 2023
Biotechnology, Pharmaceutical, Health, Consulting, Medical Devices, Professional Services, Clinical Trials, Business, Senior, Labcorp Drug Development, Council for the Central Laboratory of the Research Councils, Cornell University, Clinical trial, ChromeOS, National Health Laboratory Service, American Board of Commissioners for Foreign Missions, Global Medical Device Nomenclature, American Board of Pathology, Laboratory, Patient, Labcorp, Journal of the American Medical Directors Association, Binghamton University, Development, Quality assurance, Medidata Solutions, Medical Affairs Bureau, Oracle Health Sciences, Management

ACRO is pleased to announce that its Board of Directors has elected Paul Kirchgraber, M.D., Executive Vice President and CEO, Early Development, Central Laboratories and Global Oncology at Labcorp, as Chair effective January 1, 2023.

Key Points: 
  • ACRO is pleased to announce that its Board of Directors has elected Paul Kirchgraber, M.D., Executive Vice President and CEO, Early Development, Central Laboratories and Global Oncology at Labcorp, as Chair effective January 1, 2023.
  • Henry McNamara, Senior Vice President and General Manager at Oracle Health Sciences was elected Vice Chair.
  • from Cornell University, an M.B.A. from Binghamton University and three board certifications from the American Board of Pathology.
  • He has served on the Board of Directors for ACRO since 2019.

Thomas Pike to Join Labcorp as President and Chief Executive Officer of Its Drug Development Clinical Development Business Unit

Retrieved on: 
Thursday, January 5, 2023
Health, Science, Other Science, Pharmaceutical, Research, Chicago Board of Trade Independent Battery Light Artillery, Early Development of Global Education, EVP, Tom, Drug, Multimedia, Council for the Central Laboratory of the Research Councils, LH, Growth, Patient, NYSE, Development, Drug development, Management, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023.

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023.
  • Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp’s chairman and CEO Adam Schechter.
  • At the time of the spin-off, Mr. Pike will serve as the chief executive officer and chairman of the Board of the independent, publicly listed company.
  • In the coming months, Labcorp will announce the Board of Directors of the new company, including its lead independent director.

Global Clinical Laboratory Tests Market (2022-2027): Rising Demand for Early Disease Detection Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 22, 2022
Health Technology, COVID-19, Other Health, Pharmaceutical, General Health, Medical Devices, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Medical Supplies, Ansoff Matrix, Complete blood count, SWOT, USD, Porter's five forces analysis, Risk, Council for the Central Laboratory of the Research Councils, Growth, Investment, COVID-19, Observation, Market development, Geography, Medical device, Retail, Pharmaceutical industry

The Global Clinical Laboratory Tests Market is segmented based on Type, End-users, and Geography.

Key Points: 
  • The Global Clinical Laboratory Tests Market is segmented based on Type, End-users, and Geography.
  • By Type, the market is classified into Basic Metabolic Panel Tests, BUN Creatinine Tests, Complete Blood Count, Comprehensive Metabolic Panel Tests, Electrolytes Testing, HbA1c Tests, HGB/HCT Tests, Lipid Panel Tests, Liver Panel Tests, and Renal Panel Tests.
  • The report presents a detailed Ansoff matrix analysis for the Global Clinical Laboratory Tests Market.
  • The analyst analyses the Global Clinical Laboratory Tests Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Jacobs to Support Refurbishment of UK Nuclear Research Laboratories

Retrieved on: 
Wednesday, August 9, 2023
Securities Exchange Act of 1934, Risk, Laboratory, Dan Technology Senior Tournament of Champions, NNL, COVID-19, Twitter, NYSE, City, Securities Act of 1933, National Nuclear Laboratory, Conversation, Management, LinkedIn, Industry, Forward-looking statement, U.S. Securities and Exchange Commission, Government, Asian Infrastructure Investment Bank, Analysis, Instagram, Private sector, Financial condition report, Result, Annual report, Nuclear fission, Council for the Central Laboratory of the Research Councils, Security, Security (finance), Chemistry, Renewable energy, Sellafield, Facebook

DALLAS, Sept. 22, 2022 /PRNewswire/ -- Jacobs (NYSE:J) was selected as full lifecycle delivery partner to support infrastructure renewal projects at various facilities run by the U.K.'s government owned, but operationally independent, National Nuclear Laboratory (NNL).

Key Points: 
  • DALLAS, Sept. 22, 2022 /PRNewswire/ -- Jacobs (NYSE:J) was selected as full lifecycle delivery partner to support infrastructure renewal projects at various facilities run by the U.K.'s government owned, but operationally independent, National Nuclear Laboratory (NNL).
  • Scope includes design, build and refurbishment work at the Windscale and Central Laboratories at Sellafield in Cumbria, a specialist analytical services and process chemistry facility in Preston and a test-rig center in Workington.
  • Jacobs is responsible for: requirements definition; project specification; concept, preliminary and detailed design; procurement and installation.
  • "This work will help ensure that the U.K.'s advanced nuclear research and development capability remains world-class," said Jacobs Energy, Security & Technology Senior Vice President Karen Wiemelt.

OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board with Appointment of Nucleic Acid Therapeutics and Immunology Specialist Dr. Gunther Hartmann

Retrieved on: 
Tuesday, November 30, 2021
Teaching hospital, Hypertrophic scar, Pharmacology, Cancer, Disorder, Technology, Merck, University of Ulm, Korea, University, Institute of Liver and Biliary Sciences, United States Air Force Scientific Advisory Board, KOSDAQ, RNA interference, Therapy, Institute, Oligonucleotide, AMD, Council for the Central Laboratory of the Research Councils, Research, Clinical chemistry, GLOBE, Neuropathic pain, RNA, RNA transfection, Infection, Immunotherapy, OTS, Medical device, Vaccine

SUWON, Republic of Korea, Nov. 30, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the appointment of Dr. Gunther Hartmann to the Scientific Advisory Board of mCureX Therapeutics, a subsidiary of OliX specializing in mRNA vaccines and therapeutics.

Key Points: 
  • SUWON, Republic of Korea, Nov. 30, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the appointment of Dr. Gunther Hartmann to the Scientific Advisory Board of mCureX Therapeutics, a subsidiary of OliX specializing in mRNA vaccines and therapeutics.
  • Dr. Hartmann is a leading authority on nucleic acid therapeutics and immunology with over 20 years of experience.
  • We are pleased to welcome Dr. Hartmann to our Scientific Advisory Board.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Peer-Reviewed Article Confirms That Qualigen’s FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method

Retrieved on: 
Tuesday, October 19, 2021
Clinical trial, Orphan drug, Risk, Beckman Coulter, Cancer, Thyroid, Beckman, Private Securities Litigation Reform Act, Testosterone, AML, News, Vitamin D, Patient, U.S. Securities and Exchange Commission, Metastasis, Centralisation, Serum, Pregnancy, Security (finance), Comparison, Adult, IP, Form 10-K, FDA, Nasdaq, Time, Therapy, GLOBE, Council for the Central Laboratory of the Research Councils, American Association of Clinical Endocrinologists, Internal medicine, Survival, Acute myeloid leukemia, Method, RAS, Blood, Fastpacking, TSH, PSA, Lung cancer, Marketing, Patent, Company, Prostate cancer, Medical device, Pharmaceutical industry

All patients who participated in the study noted the advantage of the shorter time-to-result that FastPack provides.

Key Points: 
  • All patients who participated in the study noted the advantage of the shorter time-to-result that FastPack provides.
  • Investigators were able to readily obtain results much faster by FastPack (within about 15 minutes) as opposed to the 2-day response time required by Beckman ACCESS2.
  • FastPack provides rapid and accurate immunoassay tests for prostate cancer, mens health, hormone function, PSA, testosterone, thyroid disorders, pregnancy, and Vitamin D status.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence

Retrieved on: 
Thursday, October 7, 2021
ACT, Lead, PBMC, IHC, Drug resistance, Algorithm, Academia Sinica, Precision medicine, Government, Genomics, Drug development, Cancer, CAP, Council for the Central Laboratory of the Research Councils, Research, National Taiwan University, DNA sequencing, Laboratory, Center, Immunotherapy, Hope, CEO, Group, Association, FCM, Patient, NGS, Technology, Fine chemical, Medical device

The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.

Key Points: 
  • The opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia.
  • "Everyone here at CerbACT Asia is fully committed to provide high-quality results to our clients and hope to improve patient outcomes through precision medicine," says Dr George Wei, Managing Director of CerbACT Asia.
  • Together, we offer a broader range of top-notch technologies and services in Asia.
  • CerbACT Asia is an Immuno-Oncology Centre of Excellence that empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research and clinical development strategies.

Inaugural ARUP Laboratories Symposium Offers Strategies to Help Lab Leaders Advance Their Labs' Value in Their Healthcare Systems

Retrieved on: 
Wednesday, August 18, 2021
University of Maryland Medical System, MS, University, Centers for Medicare & Medicaid Services, Lessons learned, Laboratory, CPE, Department, Pressure, National Health Laboratory Service, ARUP Laboratories, Infection, Business system planning, SALT, CMS, Inside Story, Physician, Lead service line, Tata Consultancy Services, Medicare, HealthPartners, Council for the Central Laboratory of the Research Councils, ASCP, Marie Cassidy, Health, Business development, Hospital, University of Utah Hospital, MHA, ARUP, MBA, Multimedia, Lab, MSW, Supportive Services for Veteran Families, COVID-19 testing, Crisis, Patient, Case management, Spartanburg Regional Healthcare System, MLS, Medical laboratory, Experimental pathology, COVID-19, Northwell Health, Intermountain Healthcare, Management, Pharmaceutical industry, Medicine

Dowling will discuss how the pandemic has reinforced the need for governments and health systems to prepare for future infectious disease outbreaks.

Key Points: 
  • Dowling will discuss how the pandemic has reinforced the need for governments and health systems to prepare for future infectious disease outbreaks.
  • He will talk about the essential role diagnostic laboratories play in identifying viral hotspots early to slow the spread of outbreaks.
  • Visit ARUP's Lab Leadership Symposium page for an agenda and to register for the half-day event.
  • ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays.